CSL responds to class action, defends disclosure record

The CSL share price is under the microscope after it revealed it will defend a newly filed class action lawsuit.

The CSL Ltd (ASX: CSL) share price is in focus today after the company revealed it will defend a new class action alleging breaches of disclosure regulations between February 2025 and May 2026.

A sobbing businessman accused of wrongdoing faces justice

Image source: Getty Images

What did CSL report?

  • A class action has been filed in the Supreme Court of Victoria against CSL Limited.
  • The proceeding relates to alleged breaches involving certain CSL securities between 11 February 2025 and 11 May 2026.
  • Allegations centre on continuous disclosure obligations, medium-term performance guidance, and FY26 outlook communications.
  • CSL denies any wrongdoing and intends to vigorously defend itself.

What else do investors need to know?

The class action, lodged by investors who acquired CSL securities during the specified period, alleges breaches of the Corporations Act, ASIC Act, Australian Consumer Law, and ASX Listing Rules. The focus is on whether disclosures and representations about CSL's medium-term and FY26 financial performance were adequate and accurate.

CSL has responded that it maintains confidence in its compliance processes and says it has met all disclosure obligations. While legal proceedings can be uncertain, the company has signalled it will contest the claims robustly in court.

What's next for CSL?

CSL says it will defend the class action and continues to operate as normal. Investors may watch for further updates regarding the legal process and any potential impact on company operations or reputation.

The company's outlook otherwise remains unchanged. Management is focused on executing its core strategies and upholding strong governance standards.

CSL share price snapshot

Over the past 12 months, CSL shares have declined 11%, trailing the S&P/ASX 200 Index (ASX: XJO), which has fallen 2% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »